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Taking vitamins and minerals to fight against the the common cold is popular in the western 
countries and thus it is important to find out whether they are effective or not. A large number of 
trials have found that regular vitamin C supplementation shortens the duration of colds and probably 
it is beneficial when administered therapeutically, starting soon after the onset of the symptoms. Zinc 
lozenges have reduced the duration of common cold symptoms when the total daily zinc doses were 
over 70 mg. Consequently, both vitamin C and zinc have a potential for becoming options for 
treating the common cold, but more research is needed to find out optimal doses and treatment 
strategies. The prophylactic effect of vitamins and minerals has also been examined in several trials. 
Vitamin C has no preventive effect in the general community, but it may reduce the incidence of 
respiratory symptoms in restricted population groups such as people under heavy acute physical 
stress and people who have particularly low dietary intake of vitamin C. There is no evidence that 
vitamin E supplementation prevents colds in middle-aged people. Nevertheless, the effect of vitamin 
E in elderly males is heterogeneous and further studies are warranted in elderly people. -Carotene 
has been promoted for improving the immune system, but there is no evidence that it has effects 
against colds. The effects of multivitamin and multimineral combinations against the respiratory tract 
infections of elderly people have been studied in several trials, but there has been a nearly uniform 
lack of effect. Vitamin D and folic acid have been constituents of the multivitamin supplements, and 
the lack of benefit of the supplements implies that increasing the intake of vitamin D or folic acid in 





The term ‘the common cold’ does not denote any precisely defined disease, yet the symptoms of this 
illness are personally familiar to practically everybody. Although the great majority of common cold 
episodes are caused by the group of respiratory viruses, the symptom-based definition of the 
‘common cold’ also covers some diseases caused by non-respiratory viruses and even some bacterial 
infections and allergies. The large number of etiological agents, the benign character of the disease, 
and the high cost of the virologic tests (e.g., $ 700 per patient in one study [1]) mean that a 
functional everyday definition of the ‘common cold’ cannot be based on laboratory tests, but must be 
based on symptoms. Furthermore, a chest x-ray has no relevance in excluding pneumonia when the 
patient is not seriously ill. 
 The liberal definition of ‘the common cold’ has implications for research in the general 
community. First, it is much cheaper to count the number of respiratory-symptom episodes and the 
days of illness compared with searching for the etiologic agent. Second, the general community does 
not have access to rapid tests that reveal the cause of the disease. Therefore a treatment that is 
focused on a specific agent cannot be efficiently used in the community anyway. Third, the rationale 
for vitamin and mineral supplementation is based on the assumption of non-specific effects on the 
immune system and against diverse infections. Thus, the symptom based definition is particularly 
appropriate when examining whether vitamins or minerals have non-specific effects relevant at the 
public health level. 
 The primary focus of this chapter is on the common cold type of symptoms; however, the 
border between upper respiratory infections (URI) and lower respiratory infections (LRI) is 
ambiguous. For example, computer tomography identifies many more cases of pneumonia compared 
with a chest x-ray [2], and thus a patient may have an URI simply because he or she has not been 
studied with sophisticated methods. In some trials all respiratory infections or all infections were 
combined. Those trials are not excluded from this chapter, because the great majority of infections in 
the general community are URI so that the wide definitions primarily measure the URI and the 
common cold. 
 Taking vitamins to improve health and the immune system is popular in the western countries. 
About half of the elderly in the USA take some vitamin or mineral supplements [3]. Therefore it is 
important to find out whether they have effects on respiratory infections. If vitamins or minerals are 
shown to be effective, their use may be encouraged. If they are ineffective, their use should be 
discouraged. I focus on the findings of controlled trials and describe the biological rationales only to 




In the early 1970s, Linus Pauling published a meta-analysis of four placebo-controlled trials on 
vitamin C and the common cold and concluded that there was strong evidence that vitamin C 
reduced ‘integrated morbidity’ caused by colds, meaning the combination of incidence and severity 
[4]. In a second meta-analysis Pauling restricted to the two methodologically best trials, and 
calculated a combined P=0.001 to reject the hypothesis that vitamin C equals placebo [5-7]. 
 Pauling’s proposal that vitamin C might affect infections was not novel. Vitamin C deficiency, 
scurvy, is associated with a high risk of pneumonia [8,9], and after vitamin C was identified in the 
1930s, there was much interest in its effects on infections [9-11]. In 1942, two trials with 
schoolchildren found that vitamin C reduced the incidence of colds and pneumonia [6,12-14]. After 
the World War, the Sheffield trial examined the effects of vitamin C deprivation and found that the 
mean duration of colds was 6.4 days in vitamin C-deprived subjects and 3.3 days in non-deprived 
subjects [15]. Nevertheless, these early studies did not affect the main-stream medicine which 
considered that vitamin C was effective only against scurvy. 
 Methodologically, Pauling’s work was novel as his meta-analyses were among the very first 
in medicine. Furthermore, he was a public figure because of his Nobel prizes in Chemistry (1954) and 
in Peace (1963) [14,16] and therefore his message, spread also in popular books [17,18], received 
wide audiences. Although Pauling was unable to convince the medical community of the benefits of 
vitamin C, his activity led to a series of new trials. 
 Before Pauling’s first book was published [17], only one trial had examined the effects of 
regular high-dose vitamin C, 1 g/day, on the common cold [7], whereas a dozen new trials were 
carried out within a few years after Pauling made the issue popular (Fig. 1). In the mid-1970s, the 
interest in this issue evaporated, not because of consistently negative results, but for reasons 
described at the end of this section. 
 In his analyses, Pauling used ‘integrated morbidity’ - the combination of incidence and 
severity. However, the effects of vitamin C on the incidence and severity of colds are different and it 
is more useful to analyze them separately. 
 
Incidence of the common cold 
 
In our Cochrane review on vitamin C and the common cold, we restricted to placebo-controlled 
trials which used 0.2 g/day of vitamin C [24]. We used the number of participants catching a cold 
as the incidence outcome, and analyzed separately trials in the general community and trials with 
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participants under heavy acute physical stress. In 24 general community trials with 10,708 
participants, vitamin C had no effect on common cold incidence: RR=0.98 (95% CI: 0.95-1.00). In 
another meta-analysis restricting to the six largest trials which had used 1 g/day of vitamin C, the 
5480 common cold episodes were divided equally between the vitamin C and placebo groups: 
RR=0.99 (0.93-1.04)[22]. 
 Thus, there is strong evidence that vitamin C does not reduce the average incidence of colds 
in the general western populations. However, the picture is more complex than indicated by the 
narrow confidence intervals of the above meta-analyses. It is possible that vitamin C affects 
susceptibility to the common cold under special conditions or in specific subpopulations. 
 In 1996 I pooled the results of three trials with participants under heavy acute physical stress 
and found that vitamin C halved the incidence of colds: RR=0.50 (95% CI: 0.35-0.69)[25]. 
Thereafter three new trials with similar participants reported consistent results [14,24,26]. Four of 
the six trials were with marathon runners [20,27-29], one with Canadian troops in a short winter 
exercise [30], and one with Swiss schoolchildren in a skiing camp in the Swiss Alps [7]. Thus, the 
conditions were extraordinary. Furthermore, even though the authors of the six papers thought that 
they were measuring the common cold, the etiology of the recorded respiratory symptoms is not 
evident. Running for hours causes severe physical stress to the airways and can cause exercise-
induced bronchoconstriction (EIB) [31]. Thus, cough and sore throat after a marathon run does not 
necessarily imply a viral cause. Possibly the respiratory symptoms in the six trials were caused by the 
combination of viral infections and EIB. In three laboratory studies vitamin C prevented EIB [32-
34]. Thus, the benefit of vitamin C in the six trials with physically stressed participants may be 
caused by effects against both viral infections and EIB. 
 A further subpopulation in which vitamin C supplementation may affect common cold 
incidence is people who have low dietary vitamin C intake, ‘marginal deficiency.’ Among the western 
countries, dietary vitamin C intake has been particularly low in the UK [22]. In four trials with 
British males, vitamin C supplementation reduced common cold incidence: RR=0.70 (95% CI: 0.60-
0.81) whereas in four trials with females it had no effect: RR=0.95 (0.86-1.04)[12,22,35-38]. 
Substantial divergence between sexes was also seen in two trials that reported results separately for 
both sexes [38-40]. The most direct evidence supporting the ‘treatment of marginal deficiency’ -
explanation is the trial by Baird et al. as they administered only 0.08 g/day of vitamin C, yet vitamin 
C had significant effect [22,38]. Modification of vitamin C supplementation effect by dietary vitamin 
C was also suggested by the Anderson et al. trial in Canada [41], as they found greater benefit of 
vitamin C for those who had low intake of juices (Table 1); however, their subgroup analysis was not 
focused on incidence but on the total number of sickness days during the trial. Anderson also found 
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other differences between subgroups so that regular vitamin C supplementation appeared more 
beneficial for people who had contact with children, were often in crowds, or had often colds (Table 
1). 
 
Duration and severity of the common cold 
 
Regular vitamin C administration reduces the duration of colds that occur during the 
supplementation period. In 18 trials with 7242 adults, 0.2 g/day of vitamin C reduced the duration 
of colds on average by 8% (P=0.002) and in 12 trials with 2434 children by 13% (P=0.0008) [24]. 
However, these P-values underestimate the differences between the study groups, because the 
calculations are based on the duration of symptoms. For the patient and the society, the days off 
work or school, or the subjective severity may be much more relevant outcomes than the period the 
nose is running, and vitamin C might have a different effect on different outcomes. 
 With 615 Swedish schoolchildren, Ludvigsson et al. [43] found that 1 g/day vitamin C 
shortened the symptoms of URI by just 6% (P=0.6), but the ‘absence from school’ because of URI 
by 14% (P=0.016). With 818 Canadian adults, Anderson et al. [41] found that common cold 
symptoms were shortened by 5% (P=0.3), but days ‘confined to house’ because of colds were 
shortened by 21% (P=0.015). 
 There is evidence suggesting dose-dependency in the vitamin C effect [44]. In five trials with 
adults administered 1 g/day of vitamin C, the mean decrease in cold duration was only 7%, whereas 
in two trials with children administered 2 g/day the mean decrease was four times higher, 26% 
[14,44-46]. Children administered 1 g/day and adults administered 2 g/day were in the middle [44]. 
This pattern of results supports dose dependency, given also the lower average weight of children. 
Nevertheless, the outcomes and study conditions vary between trials hampering the comparison of 
different trials. The most direct evidence indicating dose-dependency was seen in the Karlowski trial 
with adults in which 6 g/day caused twice the decrease in common cold duration compared with the 
dose of 3 g/day [44,47,48]. Thus, it seems possible that trials with low doses give an underestimate 
of the potential benefit of vitamin C. 
 
Therapeutic effect of vitamin C 
 
The great majority of vitamin C trials examined the effect of regular supplementation, meaning that 
the vitamin was administered each day over the trial. However, if the purpose is to alleviate common 
cold symptoms, it is much more reasonable to administer vitamin C therapeutically, starting 
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immediately after the first symptoms. Unfortunately, few therapeutic trials have been carried out and 
their results are heterogeneous. Some of the negative findings may be explained by a low dose or a 
short treatment of 3 days or less [14,19,44,49].  
 In a 5-day therapeutic trial, Anderson et al. administered 1.5 g of vitamin C on the first day 
and 1 g/day on the following days [42]. They found a 25% reduction in ‘days confined indoors’ and 
a 29% reduction in ‘days felt feverish’ (P<0.05 for both). Anderson also found variation between 
subgroups so that therapeutic vitamin C seemed more beneficial for people who had contact with 
children or low intake of juices (Table 1). Karlowski tested 5-day therapeutic supplementation of 3 
g/day of vitamin C and found that the duration of colds was decreased by 10% (P=0.10) [47,48]. 
 In their 1974 trial, Anderson et al. compared 4 grams and 8 grams when administered only on 
the first day of the common cold [50]. In the 8-gram group, 46% of colds lasted for just one day, 
whereas in the 4-gram group, 39% of colds lasted for one day only. Thus, about 6% of participants 
found benefit from the 8 grams on the first day of the cold in the form of cold lasting just one day 
instead of longer (P=0.046, [14 p. 42]). Thus, this comparison indicates dose dependency in a 
therapeutic setting. 
 In the regular supplementation trials, the effect of vitamin C has been greater on children than 
on adults, but no therapeutic trials with children have been carried out. 
 Vitamin C is safe in high doses. For example, in a pharmacokinetic study, 100 g of vitamin C 
was administered intravenously over a few hours without reported adverse effects, and this led to 
plasma concentrations that were 100 times the level reached by oral administration of high doses 
[51]. High intravenous vitamin C doses, up to 65 g twice per week, have been administered for 
cancer patients for 10 months [52] also indicating the safety of vitamin C. Several reviewers have 
concluded that vitamin C is safe in long term use in doses ranging to several grams per day [53,54].  
Thus, there is no justification to assume that therapeutic high dose administration of vitamin C for 
colds for the duration of a week would cause harmful effects. 
 Finally, although a tablet is practical and the most common form of administering vitamin C, 
it is worth noting that administering vitamin C powder directly into the nose has also been suggested 
for treating the common cold [55]. 
 
Mechanism of the effect by vitamin C 
 
Proponents of evidence-based medicine emphasize that the evaluation of interventions should be 
based on controlled trials and not on the biological plausibility. Therefore this chapter is focused on 
trials. Nevertheless, dozens of studies have found that vitamin C may affect, for example, 
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phagocytosis and chemotaxis of leucocytes, replication of viruses, and production of interferon 
[11,56-60]. Vitamin C is an efficient antioxidant and the effects on the immune system can be 
explained by the protection against oxidative stress generated during infections [19,61-65]. Dozens 
of animal studies found that vitamin C reduces the incidence and severity of bacterial and viral 
infections indicating that the vitamin has physiological effects on infections, and not just on 
laboratory measures of the immune system [66]. Furthermore, heavy physical stress generates 
oxidative stress [67,68] and the antioxidant role of vitamin C can thus explain also its effects on 
respiratory symptoms in physically stressed people. 
 
Problems in influential papers on vitamin C and the common cold 
 
Given the evidence by 1975 indicating that regular 2 g/day vitamin C reduces the duration and 
severity of colds, at the level of P=0.000002 [69], it is puzzling that major textbooks have rejected 
the possibility that vitamin C might be beneficial against colds [14]. The interest in vitamin C and 
colds disappeared in the middle of the 1970s (Fig. 1). This waning interest was caused by the 
publication of two negative reviews in wide-circulation journals [70,71] and a particularly influential 
trial, carried out at the National Institutes of Health and published in JAMA, which concluded that 
the apparent benefit of vitamin C was explained by the placebo effect [47]. Furthermore, the 
Karlowski trial [47] and the Dykes and Meier review [71] were published in the same issue of JAMA, 
and Thomas Chalmers, a pioneer of controlled trials, was both the principal investigator of the 
Karlowski trial [47] and the author of the other review [70]. For such reasons this package of three 
papers from 1975 still has great impact on discussions on vitamin C and the common cold. 
 Chalmers’ 1975 review [70] contains a large number of serious errors, such as the data was 
inconsistent with the original published data, there were errors in calculation, the selection of trials 
was inconsistent, and in some trials a clinically less meaningful outcome was selected [72,73]. Dykes 
and Meier’s 1975 review was also biased [69,74] and Pauling wrote a commentary on their review 
and submitted his manuscript to JAMA. However, Pauling’s manuscript was rejected even after he 
twice made revisions to meet the suggestions of the referees and the manuscript was finally published 
in a minor journal [75,76]. The rejection of Pauling’s commentary was quite a strange policy by 
JAMA, since the readers were thereby prevented from seeing the other side of an important scientific 
controversy. 
 In their 1975 trial, Karlowski et al. carried out a subgroup analysis by the guessing of 
treatment by the participants and concluded that: “The effects demonstrated might be explained 
equally well by a break in the double blind” [47]. However, they excluded 42% of recorded common 
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cold episodes from their subgroup analysis without any explanations and their ‘placebo effect’ 
explanation is not even consistent with the data they reported [48,77-79]. 
 Some other reviews on vitamin C and the common cold [80,81] are also biased [69,82,83]. 
However, their impact in the medical literature is far lower than that of the three papers from 1975 
described above. Nevertheless, the problems in these other reviews also show that there is wide 
spread bias against the potential benefits of vitamin C against the common cold. 
 On his part, Pauling was too optimistic of the potential benefits of vitamin C [44,49,84]. The 
benefit in the two methodologically best trials analyzed by him [5] can be explained by the low 
dietary vitamin C intake during the war years in the USA [6] and heavy acute physical stress [7], 
and, while those findings probably reflect real biological effects, they cannot be extrapolated to the 
general western communities. Nevertheless, Pauling was correct in his conclusion that the effects of 




Vitamin E has diverse effects on the immune system, which have been assumed to be beneficial 
[60,85,86]. However, in two studies vitamin E supplementation reduced the bactericidal activity of 
leukocytes indicating that it can also cause harms on the immune system [87,88]. In dozens of animal 
studies vitamin E protected against viral and bacterial infections [66]; but increased the severity of 
infections in a few [89-91]. 
 Two trials examined the effect of 200 mg/day vitamin E on acute respiratory infections in 
people older than 60 years [92,93]. Graat et al. carried out a 15-month trial with 652 
noninstitutionalized Dutch people [92]. Vitamin E had no effect on the number of respiratory 
infections, but, paradoxically, it made the episodes more severe. In the vitamin E group, there were 
more participants with fever (P=0.009) and restriction of activity (P=0.02), and the median number 
of symptoms was higher (P=0.03) and the total duration of illness was longer (P=0.02). Thus, 
vitamin E was harmful for this population and the trial should not be dismissed when considering the 
potential harms of vitamin E supplementation [94]. 
 Meydani et al. carried out a one-year trial with 617 nursing home residents in the USA [93]. 
They reported the intention-to-treat results, favoured by biostatisticians, in table 3 calculating 13 
separate comparisons between the vitamin E and placebo groups. Thus, the table is an example of 
the multiple comparisons problem. If we calculate 20 statistical tests, when no real difference exists, 
random variation generates on average one false positive finding, P<0.05. The 13 calculations found 
only one significant difference and very marginally so: P=0.048 [93]. Therefore the variations in their 
table 3 are explained by chance, yet the authors made an unjustified extrapolation that vitamin E 
supplementation would lead to ”more than 5 million fewer elderly nursing home residents contracting 
upper respiratory infections in a year” in the USA [95]. 
 The large scale ATBC Study with 29,133 Finnish male smokers examined the effects of 6-
year vitamin E supplementation [96]. Vitamin E, 50 mg/day, had no overall effect on common cold 
incidence: RR=0.99 [97]. However, there was heterogeneity so that age and smoking modified the 
effect of vitamin E (Fig. 2, Table 2). In the young and less smoking males vitamin E increased the 
incidence of colds. In the old males, the effect diverged so that vitamin E increased the incidence of 
colds in heavy smokers but reduced it in those who smoked less. Smoking also modified the effect of 
vitamin E on pneumonia risk, reducing the risk in those who were least exposed to smoking [99]. 
 Heavy exercise causes oxidative stress and, as an antioxidant, vitamin E might protect against 
it [67,68]. In the ATBC Study, vitamin E had no effect on the incidence of colds in those who 
exercised at their leisure time [100] but halved the incidence of pneumonia [101]. 
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 Thus, in the ATBC Study vitamin E supplementation increased, decreased or had no effect on 
the incidence of the common cold, depending on age and the level of smoking. The numerical 
estimates of Table 2 are less essential than the evidence of heterogeneity. When the effect of vitamin 
E depends on the characteristics of people, the estimates of intervention effect obtained in a trial or a 
subgroup cannot be confidently generalized to other population groups. 
 The firm evidence of heterogeneity in the effect of vitamin E on respiratory infections refutes 
the notion that it is noneffective for all people. Nevertheless, the effect of vitamin E on the common 
cold is modest even in the old and less smoking males (Table 2). Considering the cost of taking 
supplements over a year, and the mild character of the disease occurring less frequently than once 
per year, it does not seem justified to propose any people to take vitamin E to prevent respiratory 
infections. Furthermore, vitamin E has increased the incidence and severity of respiratory infections 





The carotenoids is a group of hundreds of pigments that are widespread in plants, of which only 
about a dozen occur in human food. -Carotene is important as a precursor of vitamin A, but there is 
also interest in the effect of -carotene per se on health. -Carotene has effects on the immune 
system and it has been considered potentially beneficial for improving the immune system in aged 
people [60,85,102,103]. However, few controlled trials have examined the effect of -carotene on 
infections. 
 In the ATBC Study, 20 mg/day -carotene had no overall effect on the incidence of the 
common cold: RR=1.00 [97]. Nevertheless, there was significant age- and smoking-dependent 
variation in the -carotene effect. In the young and less smoking participants and in the old heavily 
smoking participants, -carotene increased the incidence of colds, but had no effect in other 
subgroups (Fig. 3, Table 3). Smoking also modified the effect of -carotene on pneumonia risk [99]. 
 In several multivitamin-multimineral trials with old people, -carotene was one constituent of 
the supplements in the range of 1.2 to 6 mg/day (next section). These trials did not find benefit of 
supplementation, which refutes the notion that increasing -carotene intake might effectively reduce 
respiratory infections in old people. 
 -Carotene is an antioxidant and potential benefits might be emphasized in physically stressed 
people. In the ATBC Study, -carotene increased the incidence of colds in males who exercised 
heavily at leisure: RR=1.25 (95% CI: 1.09-1.44) [100]. In physically active ATBC Study 
participants, -carotene nonsignificantly increased pneumonia risk [101]. 
 Two large trials found that -carotene supplementation increased mortality of people who 
had been smoking cigarettes or exposed to asbestos [96,104]. Given the harmful effects of -
carotene, as seen by the increase in respiratory infections and mortality, self-supplementation should 
be discouraged. There should be firm justification for further trials exposing people to it.
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Multivitamin and multimineral supplements 
 
If a multivitamin-multimineral supplement has no effect on infections, it seems justified to argue that 
there is a lack of effect by each constituent of the supplement. Another way to interpret a negative 
finding is to assume that some constituent is beneficial, whereas some other constituent(s) annuls 
that benefit, but such reasoning requires explicit supportive evidence. In contrast, if a multivitamin-
multimineral group does differ from the placebo group, we cannot draw specific conclusions because 
the effect can be caused by any single substance or the combination of several of them together. In 
this respect the implications are quite different when the result of a multivitamin and multimineral 
trial is positive or negative. 
 The multivitamin-multimineral trials have examined old people with the rationale that 
nutritional supplements, and antioxidants in particular, might prevent the decline in immune functions 
of the aged [85]. The frequently cited multivitamin-multimineral trial by Chandra [105] is excluded 
because a later paper based on the same data was shown to be fabricated and severe suspicions of 
the original 1992 paper were also expressed [106-108]. 
 The definition of infection outcome has been variable in the trials of Table 4. Whereas Liu et 
al. separated URI and LRI [114], the majority of the trials combined all respiratory infections or all 
infections together. However, the majority of infections in the general community consists of URI, 
and therefore the group of all infections largely reflects the incidence of the URI. 
 There is a nearly uniform lack of benefit from multivitamin and multimineral 
supplementation against respiratory infections (Table 4). Girodon et al. found reduction in infections 
by the combination of zinc and selenium [110]. However, no effect of zinc and selenium was found 
in the larger trial by the same authors [111], or in trials which included zinc or/and selenium in their 
supplements [92,109,113,114]. 
 Another positive result was by Barringer et al. with type 2 diabetics [112]. The effect of 
vitamin E was divergent between participants who had diabetes and those who did not have (Table 
4). Still, the results are odd. Among the non-supplemented participants, infections were more 
common in the diabetic participants: 92% (25/27), compared with the non-diabetics: 60% (24/40), 
which is reasonable because susceptibility to infections is higher in diabetics. However, the incidence 
of infections was substantially lower in supplemented diabetics: 17% (4/24), than in supplemented 
non-diabetics: 59% (23/39). This is illogical because it means that supplementation would make 
diabetics more resistant to infections than non-diabetics. Thus, Barringer’s findings with the small 
number of diabetics (n=51) should be considered as a justification for further trials but not for 
supplementing diabetics with vitamins. 
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 Excluding the two positive findings leaves no evidence that multivitamins and multiminerals 
would influence the risk of respiratory infections in old people (Table 4). Furthermore, following the 
argument of the first paragraph of this section, these trials also indicate that none of the following 
substances has a substantial effect on respiratory infections in the old people: vitamin D, folic acid, 
vitamin A, thiamin, riboflavin, niacin, pyridoxine, panthotenic acid, cyanocobalamin, iodide, iron, 
calcium, magnesium, manganese and copper, because they were included in the supplement of four 
or more of the trials in Table 4. 
 The findings of the trials in Table 4 indicate that there is so far no justification to supplement 
old people with vitamins for the purpose of reducing respiratory infections. Nevertheless, the 
heterogeneity seen in the ATBC Study complicates this question (Figs 2 and 3). Vitamin E and -
carotene had no effect in participants who were somewhat over 60 years, whereas both substances 
had significant effects on those who were over 70 (Tables 2 and 3). The multivitamin-multimineral 
trials of Table 4 are small, with a maximum of 1809 infection episodes recorded in Avenell’s trial 
[113]. In contrast, Fig. 2 is based on 55,770 common cold episodes providing statistical power to 
carry out subgroup analyses of age-dependency. Thus, there is justification to study the effects of 
vitamin E in old people, even though the multivitamin supplements containing vitamin E did not find 




Zinc deficiency affects the immune system and increases the risk of infections. In developing 
countries zinc supplementation has reduced the risk of childhood pneumonia [115-117] and in 
Turkey zinc reduced the risk of the common cold in children [118,119].  Although these studies 
indicate that the level of zinc intake has clinically important effects on the immune system, the 
findings cannot be extrapolated to developed countries.  For example, multivitamin-mineral 
supplements containing 10-22 mg/day zinc had no effect on the incidence of respiratory infections in 
old people (Table 4). 
 In developed countries the interest in zinc for treating the common cold is primarily based on 
the rationalization that zinc lozenges may cause local effects in the oral cavity. The research on zinc 
lozenges for treating the common cold started from a serendipitous observation that colds of a young 
child with leukemia disappeared when she started to dissolve therapeutic zinc tablets in her mouth 
instead of swallowing them [120]. 
 Zinc has various effects on the immune system [121], inhibits the replication of rhinovirus and 
respiratory syncytial virus [122-124], and enhances the effect of interferon [125]. Non-immune 
mechanisms have also been proposed to explain the effect of zinc lozenges on the common cold 
[126,127]. For the interpretation of the controlled trials with zinc lozenges, the most essential 
hypothesis is that the level of free zinc ions is a crucial determinant of efficacy [128-133]. 
 
Effect of zinc lozenges on the duration of common cold symptoms 
 
Table 5 lists the placebo-controlled trials in which the effect of zinc lozenges on natural common 
cold infections was studied. The trials are ordered by the calculated total daily dose of zinc from the 
lozenges. The reporting of outcomes is somewhat variable, but most trials reported the average 
duration of colds. The table shows that a large proportion of the variation in the results can be 
explained by the zinc dosage. None of the five trials that used less than 70 mg/day of zinc found 
effect, whereas seven of the eight trials that used over 70 mg/day of zinc found significant benefit of 
the lozenges. Evidently, the 70 mg/day should not be considered as a biological limit, instead it is a 
pragmatic limit for analyzing the trials by zinc dosage.  
 In Table 5 the dose-response relation is examined using the total zinc dose as the explanatory 
variable. However, this is a simplification because several of the lozenges contained substances 
which bind zinc ions, such as citrate, reducing the free zinc ion levels.  This argumentation has been 
elaborated in detail by several authors [128-133] and the arguments are not repeated here. Martin 
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assumed that chewing a zinc-citric acid lozenge would decrease the pH of saliva down to 2.3, and 
citrate does not form a complex with zinc ion at such a low pH [130]. However, Zarembo et al. 
studied the saliva of 18 human subjects, and chewing zinc-citrate lozenges resulted in saliva pH 
ranging between 3.2 and 5.0 [144]. Martin calculated that, in the presence of 2% citric acid in a 
solution at pH 5.1, only 1.5% of zinc is in the form of unbound zinc ions, which underscores the 
problem of complex formation [130]. 
 The solution chemistry of zinc complexes gives further explanations for the variations 
between the zinc trials. Godfrey et al. [135] administered a particularly high dose of zinc, but 
glycinate in the lozenge bound 80 to 90% of the zinc ion to complexes [131-133], which can explain 
the rather small benefit compared with the other trials using high zinc doses (Table 5). The lozenge 
of Douglas et al. [141] contained tartaric acid which effectively binds zinc [131,133]. 
 Two controlled trials examined the effect of 23 mg zinc lozenges on experimental rhinovirus 
colds. Whereas Al-Nakib et al. [145] found significant benefit of the zinc lozenges, Farr et al. found 
no benefit [146].  The lozenge of Farr contained 2% citric acid which bound essentially all zinc ions, 
whereas the lozenge of Al-Nakib did not form complexes of zinc ions, and this difference in the 
composition of lozenges can explain the divergence in the results [130-133]. Although the solution 
chemistry calculations of free zinc ion concentrations give further explanations to the variations 
between trials, the power of dose-response analysis can be seen even by counting the total dosage of 
zinc (Table 5). 
 Concluding from Table 5, the benefit of zinc lozenges can be obtained with substantially 
lower doses than Eby used in the first trial with zinc gluconate lozenges [120]. Four trials used zinc 
doses in the range of 80 to 90 mg per day and observed significant benefit from the lozenges. Three 
of these trials used lozenges containing zinc acetate [136,137,140] which does not involve the 
problem of forming zinc complexes [133]. 
 New trials should confirm the benefit of zinc lozenges in the dose range of 80 to 90 mg per 
day and examine whether benefit could be obtained with even lower doses with lozenges that do not 
contain substances that bind zinc ions. With the available evidence, a patient suffering from the 
common cold can test the effects of zinc lozenges as a personal experimentation. 
 
Safety of zinc 
 
In the controlled trials zinc lozenges have caused acute adverse effects, such as bad taste. However, 
none of the common cold trials reported long term harms caused by the zinc lozenges. High dose 
zinc supplementation, 150 mg/day, has been administered for therapeutic purposes over months and 
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years [147-149]. Copper deficiency has been reported as a consequence for some patients because of 
several years of high-dose zinc supplementation [148,149]. However, a six-week study did not find 
any detrimental effects of 150 mg/day of zinc on plasma copper levels [150]. Consequently, there 
does not seem to be any reason to assume that treating the common cold for a week with doses that 
have been used in the zinc lozenge trials might cause unanticipated long term harms. As regards the 
bad taste and other acute effects, the patient can simply stop taking the lozenge if such discomforts 
are annoying. 
 Nasal sprays or gels of zinc have also been studied for treating the common cold and some 
studies reported benefit. However, several cases of long lasting or permanent anosmia have been 
reported as a consequence of intranasal zinc administration [151,152]. Given the benign character of 
the common cold, anosmia is an unacceptable adverse effect. Nasal application of zinc should be 
discouraged, unless application methods will be developed that do not involve the risk of anosmia. 
 
Reviews on zinc and the common cold 
 
Given the number of placebo-controlled trials reporting highly significant benefit of zinc lozenges for 
treating the common cold (Table 5), it is puzzling that some reviews have concluded that there is no 
evidence that zinc would be beneficial against colds.  
 Jackson et al. [153,154] searched the literature on zinc and the common cold and found 
statistically significant heterogeneity between the trials. They calculated a pooled estimate of effect, 
although firm evidence of heterogeneity introduces serious doubt about the relevance of any one 
overall estimate. Instead, the main focus should be on trying to understand the sources of 
heterogeneity [155]. Although Jackson noted that some of the negative results might have been 
caused by low zinc availability, they did not carry out subgroup analysis by zinc doses. Jackson et al. 
concluded that their “meta-analysis suggests that the evidence of zinc effectiveness is still lacking” 
[154], which is based on their inappropriate pooling of the low and high dose trials together. 
 In their systematic review, Caruso et al. identified 14 zinc trials [156]. They used the quality 
scoring approach so that for the identified trials they gave one point for each of 11 quality items if it 
was satisfied. Four of the identified trials reached the maximum of 11 points, two reached 10 points, 
and eight trials reached 8 points or less. In two tables and one figure, Caruso et al. described the 
distribution of quality scores and the individual quality features of the trials. They proposed that the 
positive findings with zinc could be explained by methodological faults. 
 The approach to evaluate trial quality by a set of explicit criteria was initiated by Chalmers et 
al. in the early 1980s [157] and thereafter dozens of quality scales have been developed.  However, 
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the approach was not successful and it is discouraged for example in the Cochrane Handbook, which 
states that “the use of scales for assessing quality or risk of bias is explicitly discouraged in Cochrane 
reviews. While the approach offers appealing simplicity, it is not supported by empirical evidence” 
[158]. 
 One major problem of quality scoring is the focus on reporting in contrast to the scientific 
quality of the trial. For example, Caruso et al. give one point if there was “measurement of dropout 
rate” in the trial. This means that a trial can report high dropout rate, which means low scientific 
quality, yet the trial gets one point from Caruso et al., because the high dropout rate was reported 
explicitly. Caruso et al. give one point for “sample size calculation” which is important when a trial is 
planned, because it can show that the planned trial is too small, whereas it is irrelevant after the trial 
is published, because then the confidence interval reveals the accuracy of the result. Most of Caruso 
et al.’s remaining nine quality items have similar problems. 
 Although it is important to consider the methods of a trial, there are no simple criteria which 
describe that a trial is reliable or not. In a meta-analyses of 276 randomized controlled trial, Balk et 
al. concluded that “double blinding and allocation concealment, two quality measures that are 
frequently used in meta-analyses, were not associated with treatment effect” [159] meaning that valid 
estimates of treatment effect can be reached without them. Furthermore, Glasziou et al. pointed out 
that firm conclusions of treatment benefit can be drawn even without any control groups [160].  
 Finally, Caruso et al. did not discuss the possibility that the dose of zinc might have an effect 
on trial results, nor did they refer to any of the numerous papers that discussed the possibility that the 
level of free zinc ion might be important [128-133,161]. 
 Thus, the conclusions from Table 5 diverge from the conclusions of two groups of earlier 
reviewers, but there are reasonable explanations for the divergence in the conclusions.
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Bias against vitamins and minerals 
 
In the early 1970s, there was academic interest in the effect of vitamin C on the common cold, but 
then the interest vanished (Fig. 1). The evaporation of interest can be traced to three influential 
papers published in 1975 [47,70,71]. Although the three papers are severely biased, they have been 
used singly or as a doublet, for example, as references in nutritional recommendations, in textbooks 
of medicine, infectious diseases, and nutrition when authors argued that vitamin C has been shown to 
be useless for colds [48,69,72-79]. For example, the American Medical Association based its official 
statement that “One of the most widely misused vitamins is ascorbic acid. There is no reliable 
evidence that large doses of ascorbic acid prevent colds or shorten their duration” wholly on 
Chalmers’ 1975 review [162, p 1934]. 
 Bias against zinc lozenges is seen, for example, in Caruso et al.’s recent review [156], which 
focused on methodological features, mostly irrelevant to trial validity, without even presenting the 
study results. Furthermore, they stated that a “common deficiency [in the zinc trials] was proof of 
blinding which was lacking in 7 studies. The placebo effect in the treatment of colds was first shown 
>70 years ago and has since been demonstrated in subsequent studies”. As a justification for this 
statement, Caruso et al. referred to the doublet of the Karlowski trial [47] and the Chalmers review 
[70], although they knew that the two papers were erroneous, because I pointed that out in a 
criticism of their earlier biased review on echinacea and the common cold [163,164]. 
 Prejudice against nonconventional treatments is not limited to the common cold. Bias against 
vitamin C was documented by Richards who compared the attitudes and arguments of physicians to 
three putative cancer medicines: 5-fluorouracil, interferon, and vitamin C [165-169]. 
 Goodwin and Tangum [170] provided several examples to support the conclusion that there 
has been systematic bias against the concept that vitamins might be beneficial in levels higher than the 
minimum required to avoid classic deficiency diseases: “Throughout much of the 20th century, 
American academic medicine was resistant to the concept that micronutrient supplementation might 
prove beneficial. This resistance is evident in several ways: (1) by uncritical acceptance of bad news 
about micronutrient supplements; reports of toxic effects were rarely questioned and widely quoted; 
(2) by the scornful, dismissive tone of the discussions about micronutrient supplementation in 
textbooks of medicine, a tone avoided in most medical controversies; and (3) by the sceptical 
reaction greeting any claim of efficacy of a micronutrient, relative to other therapies; indeed, most 
claims were simply ignored.” 
 Although the proponents of evidence-based medicine emphasize the primary importance of 
controlled trials as the source of reliable knowledge of treatment effects, the possibility of 
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biologically rationalizing the method usually has a great importance [171]. Goodwin and Goodwin 
[172,173] reviewed several cases in which an effective method of treatment was erroneously rejected 
due to a lack of understanding of the physiological mechanism of the effect. They designated this 
problem ‘the tomato effect’, since the tomato was considered poisonous in the USA in the 1700s 
because several other plants in the same family were poisonous: “The tomato effect in medicine 
occurs when an efficacious treatment for a certain disease is ignored or rejected because it does not 
‘make sense’ in the light of accepted theories of disease mechanism and drug action.” 
 Finally, in a paper discussing great scientific discoveries, Barber [174] noted “Medical 
experts have a long history of resisting scientific innovations from what they define as ‘the outside’.” 
Thus, it is possible that this mechanism is a further reason for prejudices against vitamin C and zinc 
in the medical community, as the most active proponents, Pauling and Eby, are not physicians. 
 Goodwin and Tangum [170] conclude their paper on micronutrient supplements in academic 
medicine a follows: “There are only 3 important questions when evaluating a potential treatment. 
Does it work? What are the adverse effects? How much does it cost? Ideally, issues such as the 
theory underlying the treatment or the guild to which the proponents of the treatment belong should 
be irrelevant to the fundamental questions of efficacy, toxicity, and cost. The history of the response 





Regular vitamin C supplementation reduces common cold symptoms and probably vitamin C is 
beneficial when administered therapeutically, starting immediately after the onset of symptoms. 
However, few therapeutic vitamin C trials have been published, and none with children although 
regular vitamin C has greater effect on children than on adults. In the controlled trials, the largest 
doses were 6 g/day for adults and 2 g/day for children and such doses may be safely tested as a 
treatment option by common cold patients.  
 The results of zinc lozenge trials have diverged, but the divergence is explained largely by the 
variation in dosage, so that doses over 80 mg/day have quite consistently reduced the duration of 
colds. Zinc lozenges have caused high frequency of adverse effects, such as bad taste, but there is no 
evidence that zinc lozenges would cause actual long term harm. A large proportion of trial 
participants remained without adverse effects and consequently zinc lozenges might be useable by 
them. 
 Thus, both vitamin C and zinc supplementation have a potential for becoming options for 
treating the common cold. Both of them are safe in the doses that have been tested, there is strong 
evidence that they differ from placebo, they are inexpensive and, unlike the antibiotics [175], they do 
not cause harms on microbial ecology.  
 In the case of vitamin C and zinc, the most reasonable approach would seem to be to test 
them at the individual level so that the patient decides whether the benefits are worth the cost, the 
side effects and the involved efforts. This kind of approach is not different from ordinary treatments 
for acute medical problems in the community. Although a controlled trial can show that an analgesic 
differs on average from a placebo, it is the patient who decides whether a particular drug is effective 
for him or her. Thus, experimentation at the individual level may be encouraged, yet simultaneously 
more research is needed on vitamin C tablets and zinc lozenges to find out optimal doses and 
treatment strategies. 
 Vitamin C has no prophylactic effect in the general community, but it may reduce the 
incidence of respiratory symptoms in restricted population groups such as people under heavy acute 
physical stress and people who have particularly low dietary vitamin C intake. The effect of vitamin 
E on the common cold incidence is heterogeneous which means that it is not ineffective over all the 
population. Nevertheless, further studies are needed to specify the population groups that might 
possibly benefit from vitamin E supplementation. 
 Vitamin D and folic acid have been constituents in five multivitamin supplements that have 
been tested for old people. Those supplements did not prevent respiratory infections implying that 
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vitamin D and folic acid do not have substantial preventive effects against respiratory infections. 
There is no evidence suggesting that -carotene would be beneficial against the common cold, 





Links to the fulltexts or abstracts of the following reference list that are available via the internet, can 
be found at: http://www.ltdk.helsinki.fi/users/hemila/birkhauser. Some of the publications are located 
at the publisher’s pages and require permissions to be reached, but several are freely available. The 
file will be updated so that new controlled trials on the substances discussed in this chapter will be 
appended at the end of the file. 
 
1 Mäkelä MJ, Puhakka T, Ruuskanen O, Leinonen M, Saikku P, Kimpimäki M, Blomqvist S, Hyypiä T, 
Arstila P (1998) Viruses and bacteria in the etiology of the common cold. J Clin Microbiol 36: 539-542 
2 Syrjälä H, Broas M, Suramo I, Ojala A, Lähde S (1998) High resolution computed tomography for the 
diagnosis of community-acquired pneumonia. Clin Infect Dis 27: 358-363 
3 Millen AE, Dodd KW, Subar AF (2004) Use of vitamin, mineral, nonvitamin, and nonmineral supplements 
in the United States: The 1987, 1992, and 2000 National Health Interview Survey results. J Am Diet Assoc 
104: 942-950 
4 Pauling L (1971) The significance of the evidence about ascorbic acid and the common cold. Proc Natl 
Acad Sci USA 68: 2678-2681 
5 Pauling L (1971) Ascorbic acid and the common cold. Am J Clin Nutr 24: 1294-1299 
6 Cowan DW, Diehl HS, Baker AB (1942) Vitamins for the prevention of colds. JAMA 120: 1268-1271 
7 Ritzel G (1961) Kritische Beurteilung des Vitamins C als Prophylacticum und Therapeuticum der 
Erkältungskrankheiten [Critical analysis of the role of vitamin C in the treatment of the common cold]. 
Helv Med Acta 28: 63-68. Translation at: http://www.ltdk.helsinki.fi/users/hemila/T3.pdf (accessed 29 
December 2008) 
8 Hess AF (1920) Scurvy: Past and Present. Philadelphia, PA: Lippincott. A digitalized version is available at 
the Cornell University Library: http://chla.library.cornell.edu/  (accessed 29 December 2008) 
9 Robertson EC (1934) The vitamins and resistance to infection: vitamin C. Medicine 13: 190-206 
10 Perla D, Marmorston J (1937) Role of vitamin C in resistance. Parts I and II. Arch Pathol 23: 543-575, 683-
712 
11 Bourne GH (1949) Vitamin C and immunity. Br J Nutr 2: 341-347 
12 Glazebrook AJ, Thomson S (1942) The administration of vitamin C in a large institution and its effect on 
general health and resistance to infection. J Hygiene 42: 1-19 
13 Hemilä H, Louhiala P (2007) Vitamin C may affect lung infections. J R Soc Med 100: 495-498 
14 Hemilä H (2006) Do vitamins C and E affect respiratory infections? [PhD Thesis]. University of Helsinki, 
Helsinki, Finland, pp. 11-16, 35-51. Available at: http://ethesis.helsinki.fi/julkaisut/laa/kansa/vk/hemila/  
(accessed 29 December 2008) 
15 Bartley W, Krebs HA, O’Brien JRP (1953) Vitamin C Requirement of Human Adults. A Report by the 
Vitamin C Subcommittee of the Accessory Food Factors Committee. Spec Rep Ser Med Res Counc (GB) 
No. 280. HMSO, London, p. 43 
16 Mason SF (1997) The science and humanism of Linus Pauling (1901-1994). Chem Soc Rev 26: 29-39 
17 Pauling L (1970) Vitamin C and the Common Cold. San Francisco: Freeman  
18 Pauling L (1976) Vitamin C, the Common Cold, and the Flu. San Francisco: Freeman  
19 Hemilä H (1992) Vitamin C and the common cold. Br J Nutr 67: 3-16 
20 Himmelstein SA, Robergs RA, Koehler KM, Lewis SL, Qualls CR (1998) Vitamin C supplementation and 
upper respiratory tract infections in marathon runners. J Exercise Physiology online 1(2; July). Available 
at: http://faculty.css.edu/tboone2/asep/jan9.htm (accessed 29 December 2008) 
21 van Straten M, Josling P (2002) Preventing the common cold with a vitamin C supplement: a double-blind, 
placebo-controlled survey. Adv Ther 19: 151-159 
22 Hemilä H (1997) Vitamin C intake and susceptibility to the common cold. Br J Nutr 77: 59-72; discussion: 
1997;78: 857-866 
23 Briggs M (1984) Vitamin C and infectious disease: a review of the literature and the results of a 
randomized, double-blind, prospective study over 8 years. In: MH Briggs (ed.) Recent Vitamin Research. 
CRC Press, Boca Raton, FL, pp 39-82 
24 Hemilä H, Chalker EB, Treacy B, Douglas RM (2007) Vitamin C for preventing and treating the common 
 23 
cold. Cochrane Database Syst Rev CD000980 
25 Hemilä H (1996) Vitamin C and common cold incidence: a review of studies with subjects under heavy 
physical stress. Int J Sports Med 17: 379-383 
26 Hemilä H (2004) Vitamin C supplementation and respiratory infections: a systematic review. Mil Med 169: 
920-925 
27 Peters EM, Goetzsche JM, Grobbelaar B, Noakes TD (1993) Vitamin C supplementation reduces the 
incidence of postrace symptoms of upper-respiratory-tract infection in ultramarathon runners. Am J Clin 
Nutr 57: 170-174 
28 Peters EM, Goetzsche JM, Joseph LE, Noakes TD (1996) Vitamin C as effective as combinations of anti-
oxidant nutrients in reducing symptoms of upper respiratory tract infection in ultramarathon runners. S Afr 
J Sports Med 11(March): 23-27 
29 Moolla ME (1996) The effect of supplemental anti-oxidants on the incidence and severity of upper 
respiratory tract infections in ultra-marathon runners [MSc Thesis]. South Africa: University of Cape 
Town 
30 Sabiston BH, Radomski MW (1974) Health Problems and Vitamin C in Canadian Northern Military 
Operations. DCIEM Report no. 74-R-1012. Defence and Civil Institute of Environmental Medicine; 
Downsview, Ontario, Canada. 10 pp. Available at: 
http://www.ltdk.helsinki.fi/users/hemila/CC/Sabiston_1974_ch.pdf  (accessed 29 December 2008)  
31 Anderson SD, Kippelen P (2008) Airway injury as a mechanism for exercise-induced bronchoconstriction 
in elite athletes. J Allergy Clin Immunol 122: 225-235; discussion: 2008; in press   
32 Schachter EN, Schlesinger A (1982) The attenuation of exercise-induced bronchospasm by ascorbic acid. 
Ann Allergy 49: 146-151 
33 Cohen HA, Neuman I, Nahum H (1997) Blocking effect of vitamin C in exercise-induced asthma. Arch 
Pediatr Adolesc Med 151: 367-370 
34 Tecklenburg SL, Mickleborough TD, Fly AD, Bai Y, Stager JM (2007) Ascorbic acid supplementation 
attenuates exercise-induced bronchoconstriction in patients with asthma. Resp Med 101: 1770-1778 
35 Charleston SS, Clegg KM (1972) Ascorbic acid and the common cold. Lancet 299: 1401-1402 
36 Clegg KM, Macdonald JM (1975) L-ascorbic acid and D-isoascorbic acid in a common cold survey. Am J 
Clin Nutr 28: 973-976 
37 Elwood PC, Lee HP, Leger AS, Baird IM, Howard AN (1976) A randomized controlled trial of vitamin C in 
the prevention and amelioration of the common cold. Br J Prev Soc Med 30: 193-196 
38 Baird IM, Hughes RE, Wilson HK, Davies JE, Howard AN (1979) The effects of ascorbic acid and 
flavonoids on the occurrence of symptoms normally associated with the common cold. Am J Clin Nutr 32: 
1686-1690 
39 Tyrrell DAJ, Craig JW, Meade TW, White T (1977) A trial of ascorbic acid in the treatment of the common 
cold. Br J Prev Soc Med 31: 189-191 
40 Hemilä H (2008) Vitamin C and sex differences in respiratory tract infections. Resp Med 102: 625-626 
41 Anderson TW, Reid DBW, Beaton GH (1972) Vitamin C and the common cold: a double-blind trial. Can 
Med Assoc J 107: 503-508; corrections: 1973;108: 133 and 1973;108: 492 
42 Anderson TW, Beaton GH, Corey PN, Spero L (1975) Winter illness and vitamin C: the effect of relatively 
low doses. Can Med Assoc J 112: 823-826 
43 Ludvigsson J, Hansson LO, Tibbling G (1977) Vitamin C as a preventive medicine against common colds 
in children. Scand J Infect Dis 9: 91-98 
44 Hemilä H (1999) Vitamin C supplementation and common cold symptoms: factors affecting the magnitude 
of the benefit. Med Hypotheses 52: 171-178 
45 Coulehan JL, Reisinger KS, Rogers KD, Bradley DW (1974) Vitamin C prophylaxis in a boarding school. N 
Engl J Med 290: 6-10 
46 Bancalari A, Seguel C, Neira F, Ruiz I, Calvo C (1984) Valor profilactico de la vitamina C en infecciones 
respiratorias agudas del escolar [Prophylactic value of vitamin C in acute respiratory infections of 
schoolchildren]. Rev Med Chil 112: 871-876. Translation at: 
http://www.ltdk.helsinki.fi/users/hemila/T6.pdf (accessed 29 December 2008)  
47 Karlowski TR, Chalmers TC, Frenkel LD, Kapikian AZ, Lewis TL, Lynch JM (1975) Ascorbic acid for the 
common cold. JAMA 231: 1038-1042 
48 Hemilä H (1996) Vitamin C, the placebo effect, and the common cold: a case study of how preconceptions 
influence the analysis of results. J Clin Epidemiol 49: 1079-1084 
49 Hemilä H (1997) Vitamin C supplementation and the common cold: was Linus Pauling right or wrong? Int 
J Vitam Nutr Res 67: 329-335 
50 Anderson TW, Suranyi G, Beaton GH (1974) The effect on winter illness of large doses of vitamin C. Can 
Med Assoc J 111: 31-36 
51 Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, Wesley RA, Levine M (2004) Vitamin C 
 24 
pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 140: 533-537 
52 Padayatty SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ, Levine M (2006) Intravenously administered 
vitamin C as cancer therapy: three cases. CMAJ 174: 937-942 
53 Rivers JM (1987) Safety of high-level vitamin C ingestion. Ann NY Acad Sci 498: 445-454 
54 Hathcock JN, Azzi A, Blumberg J, Bray T, Dickinson A, Frei B, Jialal I, Johnston CS, Kelly FJ, Kraemer 
K, et al. (2005) Vitamins E and C are safe across a broad range of intakes. Am J Clin Nutr 81: 736-745 
55 Gotzsche AL (1989). Pernasal vitamin C and the common cold. Lancet 2: 1039 
56 Thomas WR, Holt PG (1978) Vitamin C and immunity: an assessment of the evidence. Clin Exp Immunol 
32: 370-379 
57 Beisel WR (1982) Single nutrients and immunity: vitamin C. Am J Clin Nutr 35(Feb suppl): 423-428, 460-
461 
58 Gross RL, Newberne PM (1980) Role of nutrition in immunologic function: vitamin C. Physiol Rev 60: 
255-260, 290-302 
59 Jariwalla RJ, Harakeh S (1996) Antiviral and immunomodulatory activities of ascorbic acid. Subcell 
Biochem 25: 215-231 
60 Webb AL, Villamor E (2007) Effects of antioxidant and non-antioxidant vitamin supplementation on 
immune function. Nutr Rev 65: 181-217 
61 Akaike T, Noguchi Y, Ijiri S, Setoguchi K, Suga M, Zheng YM, Dietzschold B, Maeda H (1996) 
Pathogenesis of influenza virus-induced pneumonia: involvement of both nitric oxide and oxygen radicals. 
Proc Natl Acad Sci USA 93: 2448-2453 
62 Peterhans E (1997) Oxidants and antioxidants in viral diseases. J Nutr 127: 962S-965S 
63 Akaike T (2001) Role of free radicals in viral pathogenesis and mutation. Rev Med Virol 11: 87-101 
64 Snelgrove RJ, Edwards L, Rae AJ, Hussell T (2006) An absence of reactive oxygen species improves the 
resolution of lung influenza infection. Eur J Immunol 36: 1364-1273 
65 Castro SM, Guerrero-Plata A, Suarez-Real G, Adegboyega PA, Colasurdo GN, Khan AM, Garofalo RP, 
Casola A (2006) Antioxidant treatment ameliorates respiratory syncytial virus-induced disease and lung 
inflammation. Am J Respir Crit Care Med 174: 1361-1369 
66 Hemilä H (2006) Do vitamins C and E affect respiratory infections? [PhD Thesis]. Helsinki, Finland: 
University of Helsinki; pp. 5-10, 105-131. Available at: 
http://ethesis.helsinki.fi/julkaisut/laa/kansa/vk/hemila/ (accessed 29 December 2008) 
67 Witt EH, Reznick AZ, Viguie CA, Starke-Reed P, Packer L (1992) Exercise, oxidative damage and effects 
of antioxidant manipulation. J Nutr 122: 766-773 
68 Packer L (1997) Oxidants, antioxidant nutrients and the athlete. J Sports Sci 15: 353-363 
69 Hemilä H (1996) Vitamin C supplementation and common cold symptoms: problems with inaccurate 
reviews. Nutrition 12: 804-809 
70 Chalmers TC (1975) Effects of ascorbic acid on the common cold: an evaluation of the evidence. Am J Med 
58: 532-536 
71 Dykes MHM, Meier P (1975) Ascorbic acid and the common cold: evaluation of its efficacy and toxicity. 
JAMA 231: 1073-1079 
72 Hemilä H, Herman ZS (1995) Vitamin C and the common cold: a retrospective analysis of Chalmers’ 
review. J Am Coll Nutr 14: 116-123 
73 Hemilä H (2008) Chalmers’ meta-analysis 1975. Available at:      
http://www.ltdk.helsinki.fi/users/hemila/reviews/chalmers (accessed 29 December 2008) 
74 Hemilä H (2008) The Dykes and Meier review 1975. Available at: 
http://www.ltdk.helsinki.fi/users/hemila/reviews/dykes (accessed 29 December 2008) 
75 Pauling L (1976) Ascorbic acid and the common cold: evaluation of its efficacy and toxicity. Part I. Medical 
Tribune 17(12): 18-19 
76 Pauling L (1976) Ascorbic acid and the common cold. Part II. Medical Tribune 17(13): 37-38 
77 Chalmers TC (1996) Dissent to the preceding article by H. Hemilä. J Clin Epidemiol 49: 1085 
78 Hemilä H (1996) To the dissent by Thomas Chalmers. J Clin Epidemiol 49: 1087 
79 Hemilä H (2008) The most influential trial on vitamin C and the common cold: Karlowski et al. 1975. 
Available at:  http://www.ltdk.helsinki.fi/users/hemila/karlowski (accessed 29 December 2008) 
80 Truswell AS (1986) Ascorbic acid [letter]. N Engl J Med 315: 709 
81 Kleijnen J, Riet G, Knipschild PG (1989) Vitamine C en verkoudheid; overzicht van een megadosis 
literatuur [in Dutch; Vitamin C and the common cold; a review of the megadose literature]. Ned Tijdschr 
Geneeskd 133: 1532-1535 
82 Hemilä H (2008) Truswell’s mini-review 1986. Available at: 
http://www.ltdk.helsinki.fi/users/hemila/reviews/truswell (accessed 29 December 2008) 
83 Hemilä H (2008) Kleijnen’s meta-analysis 1989. Available at: 
http://www.ltdk.helsinki.fi/users/hemila/reviews/kleijnen (accessed 29 December 2008) 
 25 
84 Hemilä H (2008) Pauling's meta-analyses 1971a,b. Available at: 
http://www.ltdk.helsinki.fi/users/hemila/reviews/pauling (accessed 29 December 2008) 
85 Meydani SN, Wu D, Santos MS, Hayek MG (1995) Antioxidants and immune response in aged persons: 
overview of present evidence. Am J Clin Nutr 62: 1462S-1476S 
86 Moriguchi S, Muraga M (2000) Vitamin E and immunity. Vitam Horm 59: 305-336 
87 Baehner RL, Boxer LA, Allen JM, Davis J (1977) Autoxidation as a basis for altered function by 
polymorphonuclear leukocytes. Blood 50: 327-335 
88 Prasad JS (1980) Effect of vitamin E supplementation on leukocyte function. Am J Clin Nutr 33: 606-608 
89 Eckman JR, Eaton JW, Berger E, Jacob HS (1976) Role of vitamin E in regulating malaria expression. 
Transact Assoc Am Physicians 89: 105-115 
90 Taylor DW, Levander OA, Krishna VR, Evans CB, Morris VC, Barta JR (1997) Vitamin E-deficient diets 
enriched with fish oil suppress lethal Plasmodium yoelii infections in athymic and scid/bg mice. Infect 
Immun 65: 197-202 
91 Garg R, Singh N, Dube A (2004) Intake of nutrient supplements affects multiplication of Leishmania 
donovani in hamsters. Parasitology 129: 685-691 
92 Graat JM, Schouten EG, Kok FJ (2002) Effects of daily vitamin E and multivitamin-mineral 
supplementation on acute respiratory tract infections in elderly persons: a randomized controlled trial. 
JAMA 288: 715-721 
93 Meydani SN, Leka LS, Fine BC, Dallal GE, Keusch GT, Singh MF, Hamer DH (2004) Vitamin E and 
respiratory tract infections in elderly nursing home residents: a randomized controlled trial. JAMA 292: 
828-836; corrections: 2004;292: 1305 and 2007;297: 1882; discussion: 2004;292: 2834 
94 Hemilä H (2005) Potential harm of vitamin E supplementation. Am J Clin Nutr 82: 1141-1142 
95 Hamer DH, Meydani SN (2004) Vitamin E and respiratory tract infections in elderly people. JAMA 292: 
2834 
96 The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group (1994) The effect of vitamin E and 
beta-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330: 1029-
1035 
97 Hemilä H, Kaprio J, Albanes D, Heinonen OP, Virtamo J (2002) Vitamin C, vitamin E, and beta-carotene 
in relation to common cold incidence in male smokers. Epidemiology 3: 32-37 
98 Hemilä H, Virtamo J, Albanes D, Kaprio J (2006) The effect of vitamin E on common cold incidence is 
modified by age, smoking and residential neighborhood. J Am Coll Nutr 25: 332-339 
99 Hemilä H, Virtamo J, Albanes D, Kaprio J (2004) Vitamin E and beta-carotene supplementation and 
hospital-treated pneumonia incidence in male smokers. Chest 125: 557-565 
100 Hemilä H, Virtamo J, Albanes D, Kaprio J (2003) Physical activity and the common cold in men 
administered vitamin E and -carotene. Med Sci Sports Exerc 35: 1815-1820 
101 Hemilä H, Kaprio J, Albanes D, Virtamo J (2006) Physical activity and the risk of pneumonia in men 
administered vitamin E and -carotene. Int J Sports Med 27: 336-341 
102 Bendich A (1989) Carotenoids and the immune response. J Nutr 119: 112-115 
103 Hughes DA (1999) Effects of carotenoids on human immune function. Proc Nutr Soc 58: 713-718 
104 Omenn GS (1998) Chemoprevention of lung cancer: the rise and demise of beta-carotene. Annu Rev Public 
Health 19: 73-99 
105 Chandra RK (1992) Effect of vitamin and trace-element supplementation on immune responses and 
infection in elderly subjects. Lancet 340: 1124-1127 
106 Carpenter KJ, Roberts S, Sternberg S (2003) Nutrition and immune function: a 1992 report. Lancet 361: 
2247-2248  
107 White C (2004) Three journals raise doubts on validity of Canadian studies. BMJ 328: 67; correction: 
2004;328: 257 
108 Smith R (2005) Investigating the previous studies of a fraudulent author. BMJ 331: 288-291  
109 Chavance M, Herbeth B, Lemoine A, Zhu BP (1993) Does multivitamin supplementation prevent infections 
in healthy elderly subjects? A controlled trial. Int J Vitam Nutr Res 63: 11-16 
110 Girodon F, Lombard M, Galan P, Brunet-Lecomte P, Monget AL, Arnaud J, Preziosi P, Hercberg S (1997) 
Effect of micronutrient supplementation on infection in institutionalized elderly subjects. Ann Nutr Metab 
41: 98-107 
111 Girodon F, Galan P, Monget AL, Boutron-Ruault MC, Brunet-Lecomte P, Preziosi P, Arnaud J, 
Manuguerra JC, Hercberg S (1999) Impact of trace elements and vitamin supplementation on immunity and 
infections in institutionalized elderly patients. Arch Intern Med 159: 748-754 
112 Barringer TA, Kirk JK, Santaniello AC, Foley KL, Michielutte R (2003) Effect of multivitamin and mineral 
supplement on infection and quality of life. Ann Intern Med 138: 365-371 
113 Avenell A, Campbell MK, Cook JA, Hannaford PC, Kilonzo MM, McNeill G, Milne AC, Ramsay CR, 
Seymour DG, Stephen AI, et al. (2005) Effect of multivitamin and multimineral supplements on morbidity 
 26 
from infections in older people (MAVIS trial): pragmatic, randomised, double blind, placebo controlled 
trial. BMJ 331: 324-329 
114 Liu BA, McGeer A, McArthur MA, Simor AE, Aghdassi E, Davis L, Allard JP (2007) Effect of 
multivitamin and mineral supplementation on episodes of infection in nursing home residents: a 
randomized, placebo-controlled study. J Am Geriatr Soc 55: 35-42; correction: 2007;55: 478; discussion: 
2007;55: 1311-1314 
115 Fischer Walker C, Black RE (2004) Zinc and the risk for infectious disease. Annu Rev Nutr 24: 255-275 
116 Aggarwal R, Sentz J, Miller MA (2007) Role of zinc administration in prevention of childhood diarrhea 
and respiratory illnesses: a meta-analysis. Pediatrics 119: 1120-1130 
117 Coles CL, Bose A, Moses PD, Mathew L, Agarwal I, Mammen T, Santosham M (2007) Infectious etiology 
modifies the treatment effect of zinc in severe pneumonia. Am J Clin Nutr 86: 397-403 
118 Kurugöl Z, Akilli M, Bayram N, Koturoglu G (2006) The prophylactic and therapeutic effectiveness of zinc 
sulphate on common cold in children. Acta Paediatr 95: 1175-1181 
119 Kurugöl Z, Bayram N, Atik T (2007) Effect of zinc sulfate on common cold in children: randomized, 
double blind study. Pediatr Int 49: 842-847 
120 Eby GA, Davis DR, Halcomb WW (1984) Reduction in duration of common cold by zinc gluconate 
lozenges in a double-blind study. Antimicrob Agents Chemother 25: 20-24 
121 Prasad AS (2008) Zinc in human health: effect of zinc on immune cells. Mol Med 14: 353-357 
122 Korant BD, Butterworth BE (1976) Inhibition by zinc of rhinovirus protein cleavage: interaction of zinc 
with capsid polypeptides. J Virol 18: 298-306 
123 Geist FC, Bateman JA, Hayden FG (1987) In vitro activity of zinc salts against human rhinoviruses. 
Antimicrob Agents Chemother 31: 622-624 
124 Suara RO, Crowe JE (2004) Effect of zinc salts on respiratory syncytial virus replication. Antimicrob Agents 
Chemother 48: 783-790 
125 Berg K, Bolt G, Andersen H, Owen TC (2001) Zinc potentiates the antiviral action of human IFN-alpha 
tenfold. J Interferon Cytokine Res 21: 471-474 
126 Novick SG, Godfrey JC, Godfrey NJ, Wilder HR (1996) How does zinc modify the common cold? Clinical 
observations and implications regarding mechanisms of action. Med Hypotheses 46: 295-302 
127 Novick SG, Godfrey JC, Pollack RL, Wilder HR (1997) Zinc-induced suppression of inflammation in the 
respiratory tract, caused by infection with human rhinovirus and other irritants. Med Hypotheses 49: 347-
357 
128 Godfrey JC (1988) Zinc for the common cold. Antimicrob Agents Chemother 32: 605-606 
129 Eby GA (1988) Stability constants of zinc complexes affect common cold treatment results. Antimicrob 
Agents Chemother 32: 606-607 
130 Martin RB (1988) pH as a variable in free zinc ion concentration from zinc-containing lozenges. 
Antimicrob Agents Chemother 32: 608-609 
131 Eby GA (1997) Zinc ion availability - the determinant of efficacy in zinc lozenge treatment of common 
colds. J Antimicrob Chemother 40: 483-493 
132 Bakar NKA, Taylor DM, Williams DR (1999) The chemical speciation of zinc in human saliva: possible 
correlation with reduction of the symptoms of the common cold produced by zinc gluconate-containing 
lozenges. Chemical Speciation and Bioavailability 11: 95-101 
133 Eby GA (2004) Zinc lozenges: cold cure or candy? Solution chemistry determinations. Biosci Rep 24: 23-39 
134 Smith DS, Helzner EC, Nuttall CE, Collins M, Rofman BA, Ginsberg D, Goswick CB, Magner A (1989) 
Failure of zinc gluconate in treatment of acute upper respiratory tract infections. Antimicrob Agents 
Chemother 33: 646-648 
135 Godfrey JC, Conant-Sloane B, Smith DS, Turco JH, Mercer N, Godfrey NJ (1992) Zinc gluconate and the 
common cold: a controlled clinical study. J Int Med Res 20: 234-246 
136 Prasad AS, Fitzgerald JT, Bao B, Beck FW, Chandrasekar PH (2008) Duration and severity of symptoms 
and levels of plasma interleukin-1 receptor antagonist, soluble tumor necrosis factor receptor, and adhesion 
molecules in patients with common cold treated with zinc acetate. J Infect Dis 197: 795-802 
137 Petrus EJ, Lawson KA, Bucci LR, Blum K (1998) Randomized, double-masked, placebo-controlled clinical 
study of the effectiveness of zinc acetate lozenges on common cold symptoms in allergy-tested subjects. 
Curr Ther Res 59: 595-607 
138 Turner RB, Cetnarowski WE (2000) Effect of treatment with zinc gluconate or zinc acetate on experimental 
and natural colds. Clin Infect Dis 31: 1202-1208; discussion in: 2001;32: 1520 
139 Mossad SB, Macknin ML, Medendorp SV, Mason P (1996) Zinc gluconate lozenges for treating the 
common cold: a randomized, double-blind, placebo-controlled study. Ann Intern Med 125: 81-88 
140 Prasad AS, Fitzgerald JT, Bao B, Beck FW, Chandrasekar PH (2000) Duration of symptoms and plasma 
cytokine levels in patients with the common cold treated with zinc acetate; a randomized, double-blind, 
placebo-controlled trial. Ann Intern Med 133: 245-252 
 27 
141 Douglas RM, Miles HB, Moore BW, Ryan P, Pinnock CB (1987) Failure of effervescent zinc acetate 
lozenges to alter the course of upper respiratory infection in Australian adults. Antimicrob Agents 
Chemother 31: 1183-1187 
142 Macknin ML, Piedmonte M, Calendine C, Janosky J, Wald E (1998) Zinc gluconate lozenges for treating 
the common cold in children: a randomized controlled trial. JAMA 279: 1962-1967 
143 Weismann K, Jakobsen JP, Weismann JE, Hammer UM, Nyholm SM, Hansen B, Lomholt KE, Schmidt K 
(1990) Zinc gluconate lozenges for common cold: a double-blind clinical trial. Dan Med Bull 37: 279-281 
144 Zarembo JE, Godfrey JC, Godfrey NJ (1992) Zinc(II) in saliva: determination of concentrations produced by 
different formulations of zinc gluconate lozenges containing common excipients. J Pharm Sci 81: 128-130 
145 Al-Nakib W, Higgins PG, Barrow I, Batstone G, Tyrrell DA (1987) Prophylaxis and treatment of rhinovirus 
colds with zinc gluconate lozenges. J Antimicrob Chemother 20: 893-901 
146 Farr BM, Conner EM, Betts RF, Oleske J, Minnefor A, Gwaltney JM (1987) Two randomized controlled 
trials of zinc gluconate lozenge therapy of experimentally induced rhinovirus colds. Antimicrob Agents 
Chemother 31: 1183-1187 
147 Simkin PA (1976) Oral zinc sulphate in rheumatoid arthritis. Lancet 2: 539-542 
148 Prasad AS, Brewer GJ, Schoomaker EB, Rabbani P (1978) Hypocupremia induced by zinc therapy in adults. 
JAMA 240: 2166-2168 
149 Hoffman HN, Phyliky RL, Fleming CR (1988) Zinc-induced copper deficiency. Gastroenterology 94: 508-
512 
150 Samman S, Roberts DC (1987) The effect of zinc supplements on plasma zinc and copper levels and the 
reported symptoms in healthy volunteers. Med J Aust 146: 246-249 
151 Jafek BW, Linschoten MR, Murrow BW (2004) Anosmia after intranasal zinc gluconate use. Am J Rhinol 
18: 137-141 
152 Alexander TH, Davidson TM (2006). Intranasal zinc and anosmia: the zinc-induced anosmia syndrome. 
Laryngoscope 116: 217-220; discussion: 2006;116: 1720-1723 
153 Jackson JL, Peterson C, Lesho E (1997) A meta-analysis of zinc salts lozenges and the common cold. Arch 
Intern Med 157: 2373-2376 
154 Jackson JL, Lesho E, Peterson C (2000) Zinc and the common cold: a meta-analysis revisited. J Nutr 
130(5S Suppl): 1512S-1515S 
155 Thompson SG (1994) Why sources of heterogeneity in meta-analysis should be investigated. BMJ 309: 
1351-1355 
156 Caruso TJ, Prober CG, Gwaltney JM (2007) Treatment of naturally acquired common colds with zinc: a 
structured review. . Clin Infect Dis 45: 569-574 
157 Chalmers TC, Smith H, Blackburn B, Silverman B, Schroeder B, Reitman D, Ambroz A (1981) A method 
for assessing the quality of a randomized control trial. Control Clin Trials 2: 31-49 
158 Higgins JPT, Green S (eds.). (2008) Cochrane Handbook for Systematic Reviews of Interventions Version 
5.0.1 [updated September 2008]. Section 8.3.3. The Cochrane Collaboration. Available at: www.cochrane-
handbook.org (accessed 29 December 2008) 
159 Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C, Lau J (2002) Correlation of quality 
measures with estimates of treatment effect in meta-analyses of randomized controlled trials. JAMA 287: 
2973-2982 
160 Glasziou P, Chalmers I, Rawlins M, McCulloch P (2007) When are randomised trials unnecessary? Picking 
signal from noise. BMJ 334: 349-351 
161 Eby GA (2008) Therapeutic effectiveness of ionic zinc for common colds [letter]. Clin Infect Dis 46: 483-
484 
162 Council of Scientific Affairs, American Medical Association (1987) Vitamin preparations as dietary 
supplements and as therapeutic agents. JAMA 257: 1929-1936 
163 Caruso TJ, Gwaltney JM (2005) Treatment of the common cold with echinacea: a structured review. Clin 
Infect Dis 40: 807-810 
164 Hemilä H (2005) Echinacea, vitamin C, the common cold, and blinding [letter]. Clin Infect Dis 41: 762-763 
165 Richards E (1988) The politics of therapeutic evaluation: the vitamin C and cancer controversy. Soc Stud 
Sci 18: 653-701 
166 Richards E (1991) Vitamin C and Cancer: Medicine or Politics? NY: St Martins Press 
167 Galloway J (1991) Crusades and rackets [book review]. Nature 353: 125 
168 Segerstråle U (1992) Vitamin C and cancer – medicine or politics [book review]. Science 255: 613-615 
169 Huxtable RJ (1992) C for controversy [book review]. Trends Pharmacol Sci 13: 82-83 
170 Goodwin JS, Tangum MR (1998) Battling quackery: attitudes about micronutrient supplements in 
American Academic medicine. Arch Intern Med 158: 2187-2191 
171 Vandenbroucke JP, de Craen AJM (2001) Alternative medicine: a mirror image for scientific reasoning in 
conventional medicine. Ann Intern Med 135: 507-513 
 28 
172 Goodwin JS, Goodwin JM (1981) Failure to recognize efficacious treatments: a history of salicylate therapy 
in rheumatoid arthritis. Persp Biol Med 31: 78-92 
173 Goodwin JS, Goodwin JM (1984) The tomato effect: rejection of highly efficacious therapies. JAMA 251: 
2387-2390  
174 Barber B (1961) Resistance by scientists to scientific discovery. Science 134: 596-602 
175 Gonzales R, Sande M (1995) What will it take to stop physicians from prescribing antibiotics in acute 
bronchitis? Lancet 345: 665-666 
 29 
Table 1: Heterogeneity in the vitamin C effect on the common cold:  
Anderson et al. trials of 1972 and 1975 
 
Subgroup Effect on the ”total days 







Daily juice   
0-3 oz -48% -33% 




Yes -46% -40% 




Yes -34% -25% 
No -17% -29% 
Usual colds:   
2 -43%  
0-1 -13%  
 
a Anderson et al. 1972 [41]: 1 g/day vitamin C was administered regularly and 3 g/day extra was 
administered during a cold episode for three days. For all participants, the effect of vitamin C on 
”total days indoors” per person was reduced by 30% (P=0.001) suggesting that there may be 
sufficient statistical power to explore subgroup differences, but the authors did not test the 
significance of the interactions. Based on Anderson’s table IV. 
 
b Anderson et al. 1975 [42] administered 1.5 g/day vitamin C on the first day of the cold and 
thereafter 1 g/day for a total of 5 days. For all participants, the effect of vitamin C on ”total days 




Table 2: Vitamin E and common cold incidence:  
modification of the effect by age and the level of smoking: 












50-54 yr     
5-14 4,972 0.340/0.289 1.18 
(1.06-1.30) 
15 28,742 0.323/0.330 0.98 
(0.94-1.02) 
0.001 
63-66 yr     
5-14 8,819 0.255/0.259 0.98 
(0.90-1.07) 
15 28,467 0.241/0.241 1.00 
(0.95-1.05) 
0.7 
69 yr     
5-14 4,755 0.193/0.260 0.74 
(0.65-0.84) 




Abbreviations: RR, risk ratio; CI, confidence interval. 
In the ATBC Study, there were three follow-up visits per year so that the annual common cold 




Table 3: -Carotene and common cold incidence: modification 















50-53 yr     
5-14 3,038 0.354/0.301 1.17 
(1.04-1.33) 
15 18,528 0.324/0.344 0.94 
(0.90-0.99) 
0.002 
58-67 yr     
5-14 23,941 0.255/0.253 1.01 
(0.96-1.06) 
15 85,820 0.260/0.259 1.00 
(0.98-1.03) 
0.9 
70 yr     
5-14 3,475 0.223/0.251 0.89 
(0.77-1.02) 




Abbreviations: RR, risk ratio; CI, confidence interval. 
In the ATBC Study, there were three follow-up visits per year so that the annual common cold 
incidence is three times the average per visit. For methods, see [98]. 
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Table 4: Multivitamins and multiminerals for respiratory infections 
Study [ref.] 
 Age, Duration of study 
a 
 
No.of episodes  
/ No.of participants b 
RR 




 Treatment Placebo   
Chavance 1993 [109] 
60 yr, 4 months 
    
vit C 90 mg  
vit E 30 mg 









Girodon 1997 [110] 
65 yr, 2 yr 
    
vit C 120 mg  
vit E 15 mg  
-carotene 6 mg 




Zn 20 mg  
Se 0.1 mg  
35/41 59/40 0.58 
(0.30-0.88) 
Infections d 
Girodon 1999 [111] 
65 yr, 2 yr 
    
vit C 120 mg  
vit E 15 mg  
-carotene 6 mg 




Zn 20 mg  
Se 0.1 mg  




Graat 2002 [92] 
60 yr, 1.25 yr 
    
vit C 60 mg  
vit E 10 mg  
-carotene 1.2 mg 
Zn 10 mg  
Se 0.025 mg  
+21 others 





Barringer 2003 [112] 
45 yr, 1 yr 
    




with infections g 
/ Not diabetic 
vit C 120 mg  
vit E 60 mg 
-carotene 6 mg  
Zn 22 mg  
Se 0.1 mg  
+18 others 
4/24 25/27 0.18 
(0.07-0.44) 
Participants  
with infections g 
/ DM type II 
Avenell 2005 [113] 
65 yr, 1 yr 
    
vit C 60 mg  
vit E 10 mg  
Zn 15 mg  
+13 others 
879/456 930/454 0.94 
(0.86-1.03) 
Contact with  
primary care  
for infections h 
Liu 2007 [114] 
65 yr, 1.5 yr 
    
187/375 212/373 0.88 
(0.72-1.07) 
URI vit C 80 mg 
vit E 44 mg 
-carotene 16 mg 
Zn 14 mg  
Se 0.02 mg  
+13 others 






All studies in this table were placebo-controlled, double-blind randomized trials. 
Abbreviations: RR, risk ratio; CI, confidence interval; URI, upper respiratory infection; LRI, lower 
respiratory infection. 
 
a Only the most relevant vitamins and minerals for this review are listed.  
 
b Many trials reported only the average number of episodes and the total number of episodes was 
calculated for this table. All RR estimates were calculated using the STATA poisson program, 
except the Barringer trial [112], which was calculated using the STATA glm program with the log-
link function. 
 
c Chavance et al. [109] collected data ”dealing with diagnosis or symptoms of respiratory, nose, 
throat, ear, skin, mouth, urinary and gynecologic infections.”  However, Chavance et al. do not 
describe what proportion of infections was respiratory. 
 
d Girodon et al. [110]: ”Only respiratory and symptomatic urogenital infections were collected.”  
However, Girodon et al. do not describe what proportion of infections were respiratory and urinary. 
 
e Girodon et al. [111]: ”Respiratory tract infections were based on clinical symptoms (cough, fever, 
and purulent sputum) and radiological test results.” However, Girodon et al. do not describe what 
proportion of respiratory infections were URI and LRI. 
 
f Graat et al. [92]: ”Main outcomes were incidence and severity of acute respiratory tract infections 
assessed using a diary in which participants, who received thorough instructions, recorded all acute 
symptoms.”  However, Graat et al. do not describe what proportion of respiratory infections were 
URI and LRI. 
 
g Barringer et al. [112]: ”42% of participants had URI, 19% had influenza-like syndromes, 7% had 
LRI. 20% of persons experienced more than one type of infection over the study year.” 
 
h Avenell et al. [113] describe that 50% of the number of days of self-reported infections were URI 
and 20% were LRI. 
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Table 5: Zinc lozenges for treating the common cold 
 








of Zn  
P b 
      
Eby 1984 [120] 65 207 3.9/10.8 -64% c <0.001 
Smith 1989 [134]  110 207 5.5/7.0 -22% d 0.02 
Godfrey 1992 [135] 73 192 4.9/6.1 -21% 0.048 
Prasad 2008 [136] 50 92 4.0/7.1 -44% <0.001 
Petrus 1998 [137] 101 89 3.8/5.1 -25% 0.008 
Turner 2000 [138] 139 80 6.0/5.5   
Mossad 1996 [139]  99 80 4.4/7.6 -42% <0.001 
Prasad 2000 [140] 48 79 4.5/8.1 -44% <0.001 
Turner 2000 [138] 139 69 5.5/5.5   
Douglas 1987 [141] 58 e 64 12.1/7.7  0.08 
Macknin 1996 [142] 249 55 9.0/9.0   
Weissman 1990 [143] 130 45 7/6   
Turner 2000 [138] 143 30 6.0/5.5   
 
All studies in this table were placebo-controlled double-blind trials. Weissman et al. [143] did not 
report the method of allocation, but all the other trials were randomized. All studies examined young 
and middle-aged adults, except the Macknin et al. [142] trial which examined schoolchildren. 
a The daily dose of zinc is calculated as the product of elemental zinc dose in the lozenge and the 
planned or counted number of lozenges per day. The lowest zinc doses in the lozenges were in the 
Weissman et al. [143] trial and in one arm of the Turner et al. trial [138]: 4.5 and 5 mg/lozenge, 
respectively, and the highest were in Eby et al. [120] and Godfrey et al. [135] trials: 23 and 23.7 
mg/lozenge, respectively.  In some trials, the used lozenges were counted [135-137,139-141] and the 
mean usage was used to calculate the total zinc per day. In other trials, the planned usage was the 
basis for the calculation so that dosage ”every 2 h awake” was interpreted as 9 lozenges per day.  
 
b The outcome is the average days of symptoms (mean or median) except when otherwise stated. 
The P-value was recalculated when appropriate data was reported in the paper. 
 
c Eby et al. [120] did not report the mean or median duration, but estimated the time half of the 
participants were cured from an exponential fit of the results. 
 
d Smith et al. [134] reported that ”subjects taking zinc gluconate had lower severity scores than those 
in the corresponding placebo group on days 4 to 7 of treatment. This difference is statistically 
significant (P=0.02).” From Smith’s figure 2, I measured the days needed for 80% reduction in 
severity score, which occurred in the 4 to 7 days time range, and thereby the effect was transformed 
to time scale for this table. Smith et al. did not observe difference between the study groups in the 
median duration of colds. 
 






Figure 1. The number of placebo-controlled trials in which 1 g/day of vitamin C was administered 
regularly to the participants over the study period. 
Regular supplementation means initiating supplementation with healthy people and continuing over 
the occurring common cold episodes. The number of studies published over the five year period is 
combined. For the list of references up to 1992, see [19]; thereafter Himmelstein et al. reported two 
trials with 1 g/day of vitamin C [20] and van Straten and Joslin reported one trial with 1 g/day of 
vitamin C [21]. In addition to the large number of trials in the 1970s, the importance of that decade 
is also reflected by the fact that 5 out of the 6 largest trials so far were carried out in the 1970s [22], 






Figure 2. Risk ratio (RR) of the common cold incidence in the vitamin E arm compared with the 
placebo arm; the ATBC Study, 1985-1993. 
Participants are divided to those who smoked 5 to 14 cigarettes per day at baseline and those who 
smoked 15 cigarettes or more. The placebo group level is marked by a thin line at the RR=1.00. 
Adding 4 knots to the spline curve of the heavy smokers improves the statistical model by 2(4 
df)=25.4, corresponding to P=0.00005. Adding 1 knot to the less smoking participants improves the 
spline model by 2(1 df)=41.4, corresponding to P=10-10. Vitamin E dose was 50 mg/day. These 
curves are based on 55,770 common cold episodes recorded for 14,573 participants. For the 






Figure 3. Risk ratio (RR) of the common cold incidence in the -carotene arm compared with the 
placebo arm; the ATBC Study, 1985-1993. 
Participants are divided to those who smoked 5 to 14 cigarettes per day at baseline and those who 
smoked 15 cigarettes or more. The placebo group level is marked by a thin line at the RR=1.00. 
Adding 3 knots to the spline curve of the heavy smokers improves the statistical model by 2(3 
df)=12.8, corresponding to P=0.005. Adding 1 knot to the less smoking participants improves the 
spline model by 2(1 df)=22.6, corresponding to P=0.000002. -Carotene dose was 20 mg/day. 
These curves are based on 55,905 common cold episodes recorded for 14,569 participants. For the 
construction of these spline models, see [98], except that the first knot was added at 54 years in 
these curves. 
 
